William J J Finlay
Overview
Explore the profile of William J J Finlay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
473
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cunningham O, Scott M, Zhou Z, Finlay W
MAbs
. 2021 Nov;
13(1):1999195.
PMID: 34780320
Antibody-based drugs, which now represent the dominant biologic therapeutic modality, are used to modulate disparate signaling pathways across diverse disease indications. One fundamental premise that has driven this therapeutic antibody...
2.
Root A, Cao W, Li B, LaPan P, Meade C, Sanford J, et al.
Antibodies (Basel)
. 2019 Sep;
5(1).
PMID: 31557987
Bispecific antibodies offer a promising approach for the treatment of cancer but can be challenging to engineer and manufacture. Here we report the development of PF-06671008, an extended-half-life dual-affinity re-targeting...
3.
Finlay W, Lugovskoy A
MAbs
. 2019 May;
11(5):809-811.
PMID: 31122133
We live in an era of rapidly advancing computing capacity and algorithmic sophistication. "Big data" and "artificial intelligence"find progressively wider use in all spheres of human activity, including healthcare. A...
4.
Finlay W, Coleman J, Edwards J, Johnson K
MAbs
. 2018 Dec;
11(1):26-44.
PMID: 30541416
Monoclonal anti-programmed cell death 1 (PD1) antibodies are successful cancer therapeutics, but it is not well understood why individual antibodies should have idiosyncratic side-effects. As the humanized antibody SHR-1210 causes...
5.
Finlay W, Bloom L, Varghese S, Autin B, Cunningham O
Methods Mol Biol
. 2016 Oct;
1485:319-338.
PMID: 27730560
High-affinity, highly specific binding proteins are a key class of molecules used in the development of new affinity chromatography methods. Traditionally, antibody-based methods have relied on the use of immunoglobulins...
6.
Finlay W, Bloom L, Grant J, Franklin E, Shuilleabhain D, Cunningham O
Methods Mol Biol
. 2016 Oct;
1485:85-99.
PMID: 27730550
Antibodies are critical reagents in many fundamental biochemical methods such as affinity chromatography, enzyme-linked immunosorbent assays (ELISA), flow cytometry, western blotting, immunoprecipitation, and immunohistochemistry techniques. As our understanding of the...
7.
Townsend S, Fennell B, Apgar J, Lambert M, McDonnell B, Grant J, et al.
Proc Natl Acad Sci U S A
. 2015 Dec;
112(50):15354-9.
PMID: 26621728
Although humanized antibodies have been highly successful in the clinic, all current humanization techniques have potential limitations, such as: reliance on rodent hosts, immunogenicity due to high non-germ-line amino acid...
8.
Tu C, Terraube V, Tam A, Stochaj W, Fennell B, Lin L, et al.
J Biol Chem
. 2015 Oct;
291(3):1267-76.
PMID: 26515064
Fully-human single-chain Fv (scFv) proteins are key potential building blocks of bispecific therapeutic antibodies, but they often suffer from manufacturability and clinical development limitations such as instability and aggregation. The...
9.
Fennell B, McDonnell B, Tam A, Chang L, Steven J, Broadbent I, et al.
MAbs
. 2013 Sep;
5(6):882-95.
PMID: 23995618
While myriad molecular formats for bispecific antibodies have been examined to date, the simplest structures are often based on the scFv. Issues with stability and manufacturability in scFv-based bispecific molecules,...
10.
Mahon C, Lambert M, Glanville J, Wade J, Fennell B, Krebs M, et al.
J Mol Biol
. 2013 Feb;
425(10):1712-30.
PMID: 23429058
We have generated large libraries of single-chain Fv antibody fragments (>10(10) transformants) containing unbiased amino acid diversity that is restricted to the central combining site of the stable, well-expressed DP47...